We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App





Sebia Presents Innovative Solutions for Screening and Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023

Sebia (Lisses, France) is showcasing its innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases at WorldLab–EuroMedLab Roma 2023. More...

At EuroMedLab Rome 2023, Sebia is highlighting the new Alegria 2 instrument, a fully automated, sample-to-result solution. The instrument utilizes ORGENTEC’s unique and comprehensive Alegria Monotest portfolio, boasting over 100 parameters. A key distinguishing feature of the Alegria system is its flexibility to run any test from the wide ORGENTEC portfolio at any given time. Physicians can request tailor-made biomarker profiles to be analyzed for individual patients, ensuring the best possible patient care.

Sebia is presenting its CAPILLARYS 3 range of capillary electrophoresis (CE) instruments, designed for complete automation, rapid protein separation, and high resolution. The Sebia CE instruments are equipped with several parallel capillaries, enabling multiple analyses to be carried out simultaneously, offering scalable throughput. The Sebia CAPILLARYS instruments are currently the most widely used CE systems in clinical labs globally. Alongside its CE capabilities, Sebia is highlighting its gel technique-based solutions. These are implemented on the HYDRASYS instruments to separate hemoglobins and detect major hemoglobin variants via electrophoresis on alkaline agarose gels.

Leveraging its extensive experience in CE technology, Sebia has also adapted it for HbA1c testing, which is being showcased at WorldLab–EuroMedLab Roma 2023. This cutting-edge technology offers labs and clinicians accurate and significant results, enhancing patient management. The clear and precise separation of different hemoglobin fractions enables accurate HbA1c measurement due to the high-resolution separation capabilities of the capillary instruments. Given Sebia’s wide offering of capillary instruments, laboratories have the freedom to choose the platform that best suits their needs, ranging from a benchtop standalone instrument to the TLA configuration.

Related Links:
Sebia


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.